Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SELECTED FINANCIAL STATEMENT - ASSETS

SELECTED FINANCIAL STATEMENT - ASSETS

9 Months Ended

Sep. 30, 2024

Balance Sheet Related Disclosures [Abstract]

SELECTED FINANCIAL STATEMENT - ASSETS

NOTE 4 — SELECTED FINANCIAL STATEMENT — ASSETS

Inventories consisted of the following (in thousands):


	September 30, 2024			December 31, 2023
Raw materials and components	$	1,218		$	1,329
Work-in-process		168			186
Finished goods		5,205			5,163
Inventory reserve		(4,981	)		(4,967	)
Total inventories, net	$	1,610		$	1,711

Prepaid expenses and other current assets consisted of the following (in thousands):


	September 30, 2024		December 31, 2023
Prepaid insurance	$	166	$	595
Prepaid expenses		364		536
Other current assets		817		596
Total prepaid expenses and other current assets	$	1,347	$	1,727

Property and equipment consisted of the following (in thousands):


	September 30, 2024			December 31, 2023
Equipment	$	387		$	383
Leasehold improvements		39			39
Furniture and fixtures		99			99
Total property and equipment		525			521
Less: accumulated depreciation		(476	)		(462	)
Total property and equipment, net	$	49		$	59

For the three months ended September 30, 2024 and 2023, depreciation expense was approximately $5,000 and $7,000, respectively. For the nine months ended September 30, 2024 and 2023, depreciation expense was approximately $17,000 and $26,000, respectively.